The purpose of this study is to prospectively compare percutaneous radiofrequency ablation (RFA) versus percutaneous laser ablation (LA) for the treatment of solid thyroid nodules.
Nodular thyroid disease is a common clinical problem whose prevalence increases with age and with a more widespread use of thyroid ultrasonography. Although most thyroid nodules are benign and need only periodic monitoring, some may require treatment for associated pressure and/or cosmetic symptoms. Although thyroid surgery is the main therapeutic approach for compressive thyroid nodules, it may be associated with several drawbacks. Long-term levothyroxine suppression treatment in elderly patients with large nodular goiters is unsatisfactory because it is ineffective. Furthermore, it is associated with adverse effects on bones and the cardiovascular system. Nonsurgical, minimally invasive treatment modalities such as percutaneous laser ablation (LA) and radiofrequency ablation (RFA) have been used to treat thyroid nodules. However no studies comparing LA and RFA have been published so far. Aims of the study 1. To evaluate whether LA and RFA cause a reduction ≥50% in the volume of thyroid nodules after 6 months and 1 year follow-up 2. To evaluate whether the features of thyroid nodules as evaluated by thyroid ultrasound, contrast-enhanced ultrasound, power-doppler and core-biopsy influence LA and RFA outcomes 3. To evaluate changes in thyroid function and thyroid autoimmunity after LA and RFA. 4. To evaluate differences between LA and RFA in terms of complications, side effects and tolerability. Patients will be recruited, treated and followed at Santa Maria Goretti Hospital in Latina, Italy, by physicians with expertise in LA and RFA. The scientific coordinator of this study is dr. Silvia Manfrini.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Single session with standardized approach: One or two fibers will be used for treatments including one to three illuminations with a fixed output power of 3 W, using the pullback technique. Energy for each emission will be 1200-1800J based on nodule volume. The treatment is performed under local anesthesia and conscious sedation.
Single session with standardized approach: A radiofrequency generator and a 17-gauge, 15-cm electrode with a 1-cm active tip will be used. A transisthmic approach along the short axis of the nodule will be used and the nodules will be managed with the moving-shot technique. 60 W of radiofrequency outpower will be used for all nodules. The treatment is performed under local anesthesia and conscious sedation
Santa Maria Goretti Hospital
Latina, Italy
Percentage of thyroid nodules with volume reduction at 6 and 12 months after treatment
Differences in the percentage of nodules with greater than 50% base volume reduction at 6 and 12 months
Time frame: 12 months
Basal Volume of Thyroid Nodules as Predictive factor of response to treatment
Basal volume in mL of the nodules will be calculated with the ellipsoid formula
Time frame: 12 months
Histopathological features of Thyroid Nodules as Predictive factor of response to treatment
% of amount of fibrosis and colloid components evaluated with score-biopsy
Time frame: 12 months
Variation in TSH levels after treatment
Variation in TSH value (mUI/ml) before and after LA and RFA
Time frame: 12 months
Variation in AbTPO and AbTg levels after treatment
Variation in AbTPO and AbTg levels (UI/ml) before and after LA and RFA
Time frame: 12 months
Complications
Differences in the rate of complications and side effects between LA and RFA
Time frame: Up to 1 year follow-up
Tolerability evaluated by McGill Pain Questionnaire
Tolerability will be evaluated by McGill Pain Questionnaire, Melzack 1975, italian version
Time frame: 0 and 6 months
Quality of Life
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Quality of Life will be evaluated by SF-36 QoL questionnaire after 6 months and 1 year in both arms.
Time frame: 6 months and 1 year